Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17137209 | COMPUTATIONAL REDUCTION VACCINE FOR COVID-19 ORIGINATING FROM CIVET SARS, BAT SARS, BETACOV BTRS, BETACOV BTRI, AND NEOROMICIA | December 2020 | June 2023 | Allow | 30 | 2 | 0 | Yes | No |
| 17057100 | BISPECIFIC ANTIBODY AGAINST RABIES VIRUS, AND APPLICATION THEREOF | November 2020 | July 2023 | Allow | 32 | 1 | 0 | Yes | No |
| 17067594 | SELF- ADMINISTRABLE DIAGNOSTIC TEST WITH INTEGRATED SWAB | October 2020 | July 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17036569 | EXTRACELLULAR VESICLES HARBORING A SPIKE PROTEIN, NUCLEIC ACIDS FOR PRODUCING THE SAME, AND METHOD OF IMMUNIZING A SUBJECT AGAINST SARS-CoV-2 USING THE SAME | September 2020 | June 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16979371 | NOVEL BACTERIOPHAGE AND THERAPEUTIC AGENT FOR BACTERIAL ENDOPHTHALMITIS | September 2020 | November 2023 | Abandon | 39 | 1 | 0 | No | No |
| 16997231 | PSEUDOTYPED INSECT BACULOVIRUS GENE TRANSFER SYSTEM AND PSEUDOTYPED BACULOVIRUS FOR SHRIMPS, CONSTRUCTION METHOD AND USE THEREOF | August 2020 | September 2023 | Allow | 37 | 1 | 1 | Yes | No |
| 16970052 | NOVEL AEROMONAS HYDROPHILA BACTERIOPHAGE AER-HYP-3 AND USE THEREOF FOR INHIBITING GROWTH OF AEROMONAS HYDROPHILA BACTERIA | August 2020 | August 2023 | Allow | 36 | 1 | 0 | No | No |
| 16988025 | METHODS AND SYSTEMS OF PCR-BASED RECOMBINANT ADENO-ASSOCIATED VIRUS MANUFACTURE | August 2020 | June 2024 | Allow | 46 | 2 | 1 | Yes | No |
| 16966504 | CAMPAIGN-READY SERIES OF RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV) COMPLEMENTING PLASMIDS | July 2020 | September 2023 | Allow | 38 | 1 | 0 | No | No |
| 16966472 | Improved methods and culture media for production, quantification and isolation of bacteriophages | July 2020 | June 2024 | Allow | 46 | 1 | 0 | No | No |
| 16964429 | RECOMBINANT VIRAL VACCINES | July 2020 | September 2024 | Abandon | 49 | 2 | 0 | No | No |
| 16962881 | Genetically Engineered Bacteriophage | July 2020 | June 2024 | Abandon | 47 | 1 | 1 | No | No |
| 16926732 | Separation and Quantification of Empty and Full Viral Capsid Particles | July 2020 | March 2023 | Allow | 32 | 1 | 0 | No | No |
| 16922489 | TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORS | July 2020 | April 2023 | Allow | 34 | 0 | 0 | No | No |
| 16959760 | ANTIBODY-MEDIATED NUTRALIZATION OF CHIKUNGUNYA VIRUS | July 2020 | July 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 16812125 | T-Cell Modulatory Multimeric Polypeptide with Conjugation Sites and Methods of Use Thereof | March 2020 | January 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 16642599 | COMPOSITION AND METHOD FOR INCREASING PRODUCTION OF BACTERIOPHAGE USING REACTIVE OXYGEN SPECIES | February 2020 | November 2023 | Allow | 44 | 1 | 0 | Yes | No |
| 16324744 | INFECTIOUS BRONCHITIS (IB) VIRUS VARIANTS AND RELATED COMPOSITIONS, USES AND METHOD | February 2019 | January 2024 | Abandon | 60 | 1 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner WANG, RUIXUE works in Art Unit 1648 and has examined 18 patent applications in our dataset. With an allowance rate of 66.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 38 months.
Examiner WANG, RUIXUE's allowance rate of 66.7% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by WANG, RUIXUE receive 1.06 office actions before reaching final disposition. This places the examiner in the 9% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by WANG, RUIXUE is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +54.5% benefit to allowance rate for applications examined by WANG, RUIXUE. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 40.0% of cases where such amendments are filed. This entry rate is in the 62% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 97% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.